CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.
CG Oncology by the Numbers
Active clinical programs
with planned studies soon underway. See current clinical trials.
%
Complete response rate
at any time for CG0070 in combination with KEYTRUDA®
%
Complete response rate
at 12 months for CG0070 in combination with KEYTRUDA®
Investors
Latest News
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
- 85% (n=29/34) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial - May 1, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. announced updated data from the CORE-001...
New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting
April 10, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated...
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 27, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P....